On April 22, 2025, AHMU School of Pharmaceutical Sciences Nephrology Research Team published a research paper titled NAT10 Exacerbates Acute Renal Inflammation by Enhancing N4-Acetylcytidine Modification of the CCL2/CXCL1 Axis in Proceedings of the National Academy of Sciences (PNAS) (Category: Direct Submission). Meng Xiaoming, professor from School of Pharmaceutical Sciences, is the sole corresponding author, with co-first authors including Wang Jianan, Suo Xiaoguo, Yu Jutao, and Luo Qichao.
This research reveals the critical role and molecular mechanism of mRNA ac4C acetylation modification in acute renal inflammation. The study found that NAT10 in renal tubular epithelial cells simultaneously mediates the acetylation modification of mRNAs of various inflammatory chemokines such as CCL2 and CXCL1, promoting the stability of their transcripts, thereby recruiting circulating macrophages, neutrophils, and other inflammatory cells to accumulate and creating inflammatory microenvironment in the kidney. NAT10 may act as a critical regulatory “switch” in renal inflammation, promoting the onset and progression of acute kidney injury.
For further information, please see the full article:https://www.pnas.org/doi/10.1073/pnas.2418409122